Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma
NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial int
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
07:00am, Thursday, 09'th Sep 2021
Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET
BioXcel: Recent Selloff Offers A Very Good Opportunity To Entry At A Discount Price
02:32pm, Wednesday, 18'th Aug 2021
Any investor who looks at the stock price chart during this year 2021 will be shadowed by the sharp drop that it presents.
BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript
12:19pm, Tuesday, 10'th Aug 2021
BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
07:00am, Tuesday, 10'th Aug 2021
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021
This Under-the-Radar Dementia Treatment Could Reward Investors
06:25am, Thursday, 29'th Jul 2021
Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
07:00am, Wednesday, 28'th Jul 2021
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial inte
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
07:30am, Monday, 19'th Jul 2021
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Off
Here's Why BioXcel Therapeutics Stock Got Hammered This Week
02:33pm, Friday, 25'th Jun 2021
Investors weren't happy about a secondary share offering.
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
08:29am, Wednesday, 23'rd Jun 2021
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing o
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 22'nd Jun 2021
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approach
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
07:00am, Friday, 18'th Jun 2021
Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET
BioXcel: Upcoming PDUFA Makes Recent Drop Attractive
08:00am, Saturday, 29'th May 2021
BioXcel has a January 5 PDUFA for its lead candidate. The stock is down strongly.
